TEKTURNA
Clinical safety rating
cautionComprehensive clinical and safety monograph for TEKTURNA (TEKTURNA).
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
| Metabolism | Primarily hepatic via CYP3A4; minor metabolism via other pathways. Excreted in feces (78%) and urine (22%). |
| Excretion | Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%. |
| Half-life | Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing. |
| Protein binding | Approximately 50% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is approximately 2.5% (low due to limited absorption and high first-pass metabolism); absorption is reduced by high-fat meal (by up to 50%). |
| Onset of Action | Oral: Reduction in blood pressure occurs within 2 hours, with maximal effect observed by 2–4 weeks of continuous therapy. |
| Duration of Action | Dosing interval is 24 hours; blood pressure reduction is maintained over 24 hours with once-daily administration. |
| Molecular Weight | 586.6 |
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in GFR <30 mL/min/1.73 m². For GFR ≥30 mL/min/1.73 m², no dose adjustment required. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C). |
| Pediatric use | Not approved for use in pediatric patients under 18 years of age due to lack of safety and efficacy data. |
| Geriatric use | No dose adjustment required in elderly patients; initiate therapy at 150 mg once daily and monitor renal function and blood pressure closely due to increased risk of hypotension and renal impairment. |
| 1st trimester | Avoid use; potential teratogenic effects (fetal renal abnormalities, oligohydramnios) based on animal studies and limited human data. |
| 2nd trimester | Contraindicated: can cause fetal renal dysfunction, oligohydramnios, and skull ossification defects. |
| 3rd trimester | Contraindicated: increased risk of fetal and neonatal morbidity (hypotension, renal failure, hyperkalemia). |
Clinical note
Comprehensive clinical and safety monograph for TEKTURNA (TEKTURNA).
| Placental transfer | Extensive placental transfer in animal studies; human data limited but expected to cross based on molecular weight and properties. |
| Breastfeeding | Not recommended; no human data on presence in breast milk. Use alternate antihypertensive agents with more safety data. |
| Lactation Rating | L5 - Avoid |
| Teratogenic Risk | Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. First trimester exposure may also carry increased risk but is less well-defined. |
| Fetal Monitoring | Monitor fetal ultrasound for oligohydramnios if exposure occurs in second or third trimester. Assess neonatal blood pressure, renal function, and serum potassium after delivery. |
| Fertility Effects | No human data; animal studies suggest no impairment of fertility. |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyHistory of angioedema with ACE inhibitors or ARBsConcomitant use with aliskiren in diabetes mellitus
| Precautions | Fetal toxicity (avoid in pregnant women; discontinue if pregnancy detected), Hypotension in volume-depleted patients, Renal impairment (monitor renal function; risk of acute renal failure in patients with bilateral renal artery stenosis), Hyperkalemia (especially in patients with renal impairment, diabetes, or on potassium-sparing diuretics), Angioedema (discontinue immediately and manage appropriately) |
| Food/Dietary | High-fat meals reduce aliskiren absorption; avoid consistent consumption with high-fat foods. Grapefruit juice may decrease aliskiren levels; avoid concurrent intake. No other significant food interactions. |
| Clinical Pearls | TEKTURNA (aliskiren) is a direct renin inhibitor used for hypertension. Monitor renal function and potassium levels due to risk of hyperkalemia and renal impairment, especially in patients with diabetes, renal artery stenosis, or concomitant ACE/ARB use. Avoid use during pregnancy (category D). Contraindicated with cyclosporine and itraconazole due to increased aliskiren exposure. |
| Patient Advice | Take TEKTURNA once daily with or without food, but consistently either with a meal or without. · Avoid high-fat meals as they can reduce absorption. · Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. · Do not use salt substitutes containing potassium without consulting your doctor. · Report symptoms like muscle cramps, irregular heartbeat, or weakness (signs of hyperkalemia). · Stay hydrated and avoid dehydration (vomiting, diarrhea, excessive sweating) as it may increase side effects. |
Loading safety data…